Fierce Biotech May 22, 2024
Medical app developer Click Therapeutics will increase its digital reach by obtaining assets from the recently defunct Better Therapeutics, which began winding down its operations in March.
The purchase aims to jump-start Click’s work in obesity, diabetes and chronic cardiometabolic disease. Acquisitions from Better’s portfolio include AspyreRx, which received a de novo clearance from the FDA last year as the first digital therapeutic for Type 2 diabetes.
Click also picked up BT-004, a breakthrough-designated app that was being developed for metabolic dysfunction-associated steatohepatitis, also known as MASH, as well as BT-003 and BT-002, which target high cholesterol and high blood pressure, respectively.
“There is immense potential in the cardiometabolic space for next-generation ‘smart’ therapeutics that enhance patient care and...
Today's Sponsors
Today's Sponsor